Myeloma and MGUS: A Guide for GPs
This guide is written for GPs to help in the diagnosis of myeloma and monoclonal gammopathies. Primary care clinicians play a critical role in the early diagnosis of myeloma
BMJ Learning: Myeloma: Practical tips for primary care
In collaboration with BMJ Learning, we have created a new course for GPs on myeloma. This interactive course gives practical tips on the detection and diagnosis of myeloma and MGUS.
GatewayC Myeloma Early Diagnosis course
We have partnered with GatewayC on their updated Myeloma Early Diagnosis course, available for all primary care professionals.
This course aims to increase GPs’ awareness of patients with suspected myeloma and support them to undertake the appropriate investigations and understand how to interpret the results.
MUK nine results: Intensive treatment delivers deep responses in ultra-high risk myeloma patients
In June, the first results from the OPTIMUM/MUK nine clinical trial were presented at international conferences.
The trial is the first to use state-of-the-art diagnostics and genetic profiling to screen for patients with high-risk myeloma.
These results show that treatment with a five-drug induction treatment (Dara-CVRd) and stem cell transplant is effective and well tolerated in ultra-high risk myeloma patient
Mid-year update on myeloma treatment appraisals
Throughout 2021, the Patient Advocacy Team have been continuing their work to support patient access to new treatments on the NHS. Read more about the four active Health Technology Appraisals including the first-ever appraisal for an AL amyloidosis treatment.
Raising HCP awareness of myeloma
Find out more about the educational resources our Clinical Practice Services Team have been developing to raise HCP awareness of myeloma.
UKMRA -Myeloma UK-CARP webinar series
The Clinical Trials Research Unit at the University of Leeds has produced a series of webinars for researchers and clinicians about the UK Myeloma Research Alliance (UKMRA)-Myeloma UK-Concept and Access Research Programme (CARP) and how it supports the development of early phase myeloma clinical trials in the UK.